After four injections of a therapy called Anktiva, his latest scan came back normal.

The treatment has been studied for more than a decade and has shown promise across multiple cancer types, yet it’s only approved for a narrow form of bladder cancer.

Should potentially life-saving treatments move through the approval process faster for patients with no other options?